Last reviewed · How we verify
Cyclophosphamide + Doxorrubicin
This combination uses cyclophosphamide (an alkylating agent) and doxorrubicin (a topoisomerase II inhibitor) to damage cancer cell DNA through complementary mechanisms.
This combination uses cyclophosphamide (an alkylating agent) and doxorrubicin (a topoisomerase II inhibitor) to damage cancer cell DNA through complementary mechanisms. Used for Breast cancer (likely primary indication given AC regimen use), Lymphomas, Other solid tumors.
At a glance
| Generic name | Cyclophosphamide + Doxorrubicin |
|---|---|
| Also known as | Citoxan + Rubidox |
| Sponsor | Latin American Cooperative Oncology Group |
| Drug class | Chemotherapy combination (alkylating agent + anthracycline) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is a nitrogen mustard alkylating agent that cross-links DNA strands, preventing replication and transcription. Doxorrubicin intercalates into DNA and inhibits topoisomerase II, blocking DNA unwinding and repair. Together, they create synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Breast cancer (likely primary indication given AC regimen use)
- Lymphomas
- Other solid tumors
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorrubicin-related)
- Hemorrhagic cystitis (cyclophosphamide-related)
- Infection
- Fatigue
Key clinical trials
- Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer (PHASE3)
- Neoadjuvant Carboplatin in Triple Negative Breast Cancer (PHASE2)
- Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: